“…In most real-life studies, UST was used on anti-TNF-α failure or refractory patients [ 70 , 71 ]. In this specific clinical context, remission at 24 weeks and (when available) at 52 weeks ranged from 31% to 75% and 25% to 60%, respectively [ 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 ]. Moreover, mucosal healing (MH) and fecal calprotectin (FC) levels significantly improved under UST treatment [ 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , …”